ARM CEO Tobias transfers shares to associate worth R 2.62 million
Bitget2026/10/08 11:40ARM CEO V.P. Tobias received 16,624 ordinary shares via equity settlement of conditional shares under the 2018 conditional share plan. Shares were priced at a volume-weighted average R 157.8395, implying a value of R 2.62 million. Tobias transferred the 16,624 shares off-market to associate Silver Jaguar Holdings at the same R 157.8395 price, value R 2.62 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARM - African Rainbow Minerals Ltd. published the original content used to generate this news brief via SENS, the regulatory disclosure system operated by the Johannesburg Securities Exchange (JSE) (Ref. ID: S604567), on October 08, 2026, and is solely responsible for the information contained therein.
- ARM CEO V.P. Tobias received 16,624 ordinary shares via equity settlement of conditional shares under the 2018 conditional share plan.
- Shares were priced at a volume-weighted average R 157.8395, implying a value of R 2.62 million.
- Tobias transferred the 16,624 shares off-market to associate Silver Jaguar Holdings at the same R 157.8395 price, value R 2.62 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
